Japan's Astellas shows nearly 50% gain in Q1 even as sales drag on price revisions

First quarter financial year core operating profit for Tokyo-based Astellas Pharma reached ¥67.1 billion, up a tad more than 49% even as overall sales dipped on reimbursement price revisions in Japan.

However, the company said in a release that sales of Xtandi (enzalutamide) grew and aided the bottom line along with the transfer of the global dermatology business in April, part of a $727 million deal with Danish specialty product firm LEO last year.

"We are pleased with our solid performance and ability to achieve sustainable growth through increasing sales of Xtandi … and overall (bladder) treatments, new product introductions and focused investment in innovation and strengthening our base,” said Yoshihiko Hatanaka, president and CEO of Astellas.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Overall sales, however, fell nearly 6% in the first quarter ended June 30, compared to the same period a year ago, to ¥337.8 billion.

- here's the release

Related Articles:
British watchdogs suspend Astellas UK after investigations, audits, and a crackdown from Japanese HQ
Drug price cuts in Japan sink in though details sparse
Japan's Astellas eyed to buy Kaketsuken's vaccine business
Astellas' Xtandi under pressure as U.S. lawmakers push for generic swap
Japan's Astellas Pharma gets $727M for ailing dermatology unit as it swings to new areas


Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.